The adult trial failure is a setback for the HSCT-TMA program, but the pediatric path forward is intact with regulatory filings underway. The stock may see limited downside given the niche indication and Ultomiris's existing approvals in larger markets. Monitor health authority feedback on the adult indication and any pediatric approval timelines.
AZN drugs
AZN drug pipeline →How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Jul 27 $169.64entry
- T+1 · 4mo ago +1.67%α +1.43% · $172.48
- T+5 · 4mo ago 0.00%α −1.07% · $169.64
- T+20 · 3mo ago −1.75%α −5.05% · $166.68
- T+60 · 28d ago −0.48%α −4.54% · $168.82
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
AstraZeneca reported Phase III results for Ultomiris in HSCT-TMA: the adult/adolescent trial (ALXN1210-TMA-313) failed to meet its primary endpoint of event-free survival, while the pediatric trial (ALXN1210-TMA-314) showed previously disclosed clinically meaningful overall survival (87.2% at 26 weeks). The company is advancing regulatory filings for the pediatric indication, but the adult indication faces an uncertain path pending ongoing health authority discussions.
Key Facts
- Ultomiris did not achieve statistical significance for the primary endpoint (event-free survival through 26 weeks) in the Phase III ALXN1210-TMA-313 trial in adults and adolescents with HSCT-TMA.
- In the pediatric Phase III ALXN1210-TMA-314 trial, Ultomiris demonstrated clinically meaningful overall survival of 87.2% at 26 weeks and 73.4% at 52 weeks (previously disclosed).
- Alexion, AstraZeneca Rare Disease, is advancing regulatory filings for Ultomiris in pediatric HSCT-TMA based on these results and an external control study.
- Ultomiris has Orphan Drug Designation in the US and Japan for HSCT-TMA and Breakthrough Therapy designation from the FDA for pediatric patients with HSCT-TMA.
- HSCT-TMA is estimated to affect fewer than 6,000 people in the US.
Financial Impact
No financial figures provided in the filing; the indication addresses a small patient population (<6,000 in the US), so the revenue contribution is likely minimal relative to AstraZeneca's total revenue.
Risk Factors
- Regulatory path for the adult indication remains uncertain; health authorities may require additional data or reject the indication.
- Competition from other complement inhibitors or emerging therapies for HSCT-TMA.
- Narrow patient population limits commercial upside; clinical adoption may be slow without clear efficacy data in adults.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001654954-26-006897 |
| Document: 0001654954-26-006897-index-headers.html | 0001654954-26-006897 |
| Document: 0001654954-26-006897-index.html | 0001654954-26-006897 |
| Document: 0001654954-26-006897.txt | 0001654954-26-006897 |
Track record
77 reports on AZN
19 of 38 bullish or bearish reports moved the stock their way by T+5. Best: +20.72% at T+60 after the Aug 17, 2026 report. 29 of 38 went positive at some point.
Filters
- Nov 16, 2026today 6-K Bullish 6/10 Entry price pending
- Nov 16, 2026today 6-K Bullish 6/10 Entry $185.55 Now $184.02 −0.82% settles Nov 23
- Nov 16, 2026today 6-K Bullish 6/10 Entry $185.31 Now $184.02 −0.70% settles Nov 23
- Nov 16, 2026today 6-K Bullish 5/10 Entry $185.09 Now $184.02 −0.58% settles Nov 23
- Nov 4, 202612d ago Institutional Cluster Mixed 3/10 Entry $186.85 to $184.38 Now $184.02 −1.51% ▼ −1.32% −4.61% vs SPY
- Nov 2, 202614d ago 6-K Neutral 1/10 Entry $186.58 to $189.39 Now $184.02 −1.37% ▲ +1.51% +1.43% vs SPY
- Nov 2, 202614d ago 6-K Neutral 1/10 Entry $186.58 to $189.39 Now $184.02 −1.37% ▲ +1.51% +1.43% vs SPY
- Oct 30, 202617d ago 6-K Neutral 5/10 Entry $186.65 to $186.43 Now $184.02 −1.41% ▼ −0.12% +2.59% vs SPY
- Oct 27, 202620d ago 6-K Bullish 5/10 Entry $170.08 to $183.88 Now $184.02 +8.20% ▲ +8.11% +10.10% vs SPY
- Oct 22, 202625d ago 6-K Bullish 6/10 Entry $172.57 to $173.46 Now $184.02 +6.63% ▲ +0.51% −0.19% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers